Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8738584 | International Journal of Antimicrobial Agents | 2018 | 22 Pages |
Abstract
For infections caused by antibiotic-resistant Gram-negative organisms other than K. pneumoniae, clinical and microbiological success rates for patients treated with ceftazidime/avibactam were similar to those that have been reported for K. pneumoniae. Ceftazidime/avibactam appears to be a promising treatment option for infections caused by a variety of resistant Gram-negative organisms when limited alternatives exist.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Barbara A. Santevecchi, Tiffeny T. Smith, Shawn H. MacVane,